RetinaCME
VIDEOCMEABO MOC

Best of Ophthalmology Research for May 2021: Emerging Approaches in Treatment of nAMD and DME

Author(s)/Faculty: Charles C. Wykoff, MD, PhD; Mark P. Breazzano, MD
Release Date: 5/28/2021Expiration Date: 5/27/2022
Credit Type: CME / CME with ABO Continuing CertificationNumber of Credits: 0.75
Content Type: VideoProvider:
The utilization of anti-vascular endothelial growth factor therapy in treatment protocols for patients with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) has led to the enhancement of visual outcomes, yet these vision improvements are usually less than those observed in clinical studies. The differences between the real-world outcomes and clinical trials have been in part associated with loss of compliance due to treatment burden. Several strategies are currently being evaluated to address the issue of treatment burden, including delivery systems, gene therapy, and agents that extend dosing intervals while targeting novel pathways. These strategies have the potential to lengthen the dosing interval while enhancing visual acuity gains. In this CME activity, Best of Ophthalmology Research for May 2021: Emerging Approaches in Treatment of nAMD and DME, experts in the field review the latest clinical study data evaluating emerging novel delivery systems and targeted therapies that have the potential to lengthen the time between treatments for patients with nAMD and DME.